Company News from Forest Labs and Abbott Labs

Share this article:
Forest Labs agreed to settle government civil allegations that it improperly marketed antidepressants Celexa and Lexapro, as well as its Levothroid thyroid drug, the firm revealed in an SEC filing. The amount is covered under a $170,000 cash reserve. But Forest termed the pact an “agreement in principle” that is still not final and noted an ongoing criminal probe.
 
Separately, Abbott Labs said in an SEC filing that the US Department of Justice is investigating promotional activities for its CNS drug Depakote. The government is seeking to determine whether sales and marketing practices may have violated the Federal False Claims Act, the Food and Drug Cosmetic Act or the Anti-Kickback Statute.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters